Exact Sciences Posts Record $851M Q3 Revenue, Raises Full-Year Guidance

Exact Sciences Corp. reported strong third-quarter 2025 financial results, driven by significant growth in cancer screening tests such as Cologuard and Oncotype DX, with total revenues reaching $851 million, a 20% increase year-over-year. The company beat earnings expectations with adjusted earnings per share of $0.24, demonstrating an 85% earnings surprise, and raised its full-year revenue guidance to $3.23 billion, reflecting confidence in ongoing growth and margin improvements. Key drivers include increased sales force productivity, the launch of new tests like Cologuard Plus and Cancerguard, and expanded partnerships, notably with Quest Diagnostics, which together support broader patient access and enhanced early cancer detection. Exact Sciences also showed improvements in operating metrics, including operating margin and free cash flow margin, while investing strategically in sales, marketing, and research and development to sustain long-term growth. Analysts, including TD Cowen's Daniel Brennan, hold a bullish outlook on the stock, citing the company's robust performance, pipeline potential, and attractive valuation amid a re-rating of the diagnostics sector. Overall, Exact Sciences maintains a positive growth trajectory with innovation and international expansion as key pillars for its future.